The estimated Net Worth of Denise Scots Knight is at least $4.95 Миллион dollars as of 25 June 2024. Denise Knight owns over 132,985 units of Mereo BioPharma plc stock worth over $3,306,354 and over the last 8 years he sold MREO stock worth over $464,118. In addition, he makes $1,176,190 as Chief Executive Officer, Co-Founder и Executive Director at Mereo BioPharma plc.
Sign up
Denise Knight MREO stock SEC Form 4 insiders trading
Denise has made over 2 trades of the Mereo BioPharma plc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 132,985 units of MREO stock worth $464,118 on 25 June 2024.
The largest trade he's ever made was exercising 282,090 units of Mereo BioPharma plc stock on 21 June 2024 worth over $1,314,539. On average, Denise trades about 27,672 units every 0 days since 2016. As of 25 June 2024 he still owns at least 709,518 units of Mereo BioPharma plc stock.
You can see the complete history of Denise Knight stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Denise Scots-Knight biography
Dr. Denise V. Scots-Knight Ph.D. serves as Chief Executive Officer, Co-Founder, Executive Director of the Company. Dr. Scots-Knight has served as our Chief Executive Officer since July 2015 and as a member of our Board since our formation. From 2010 until joining us, Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd. (“Phase4”), a global life science venture capital firm. Dr. Scots-Knight is currently a board member of Elanco Animal Health Incorporated (NYSE: ELAN. Dr. Scots-Knight previously served as a member of the board of directors of Idenix Pharmaceuticals, Nabriva, Albireo and OncoMed. Dr. Scots-Knight holds a B.Sc. (Hons.) and a Ph.D. from Birmingham University.
What is the salary of Denise Knight?
As the Chief Executive Officer, Co-Founder и Executive Director of Mereo BioPharma plc, the total compensation of Denise Knight at Mereo BioPharma plc is $1,176,190. There are no executives at Mereo BioPharma plc getting paid more.
How old is Denise Knight?
Denise Knight is 60, he's been the Chief Executive Officer, Co-Founder и Executive Director of Mereo BioPharma plc since 2015. There are 11 older and 11 younger executives at Mereo BioPharma plc. The oldest executive at Mereo BioPharma Group plc is Peter Fellner, 76, who is the Non-Executive Independent Chairman of the Board.
What's Denise Knight's mailing address?
Denise's mailing address filed with the SEC is C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, X0, W1G 0QF.
Insiders trading at Mereo BioPharma plc
Over the last few years, insiders at Mereo BioPharma plc have traded over $974,160 worth of Mereo BioPharma plc stock. The most active insiders traders include Capital Management Lp Rosen..., Deepika Pakianathan и Denise Scots Knight. On average, Mereo BioPharma plc executives and independent directors trade stock every 8 days with the average trade being worth of $447,435. The most recent stock trade was executed by Deepika Pakianathan on 22 August 2024, trading 105,244 units of MREO stock currently worth $151,551.
What does Mereo BioPharma plc do?
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.
What does Mereo BioPharma plc's logo look like?
Complete history of Denise Knight stock trades at Albireo Pharma Inc, Elanco Animal Health Inc и Mereo BioPharma plc
Mereo BioPharma plc executives and stock owners
Mereo BioPharma plc executives and other stock owners filed with the SEC include:
-
Denise Scots-Knight,
Chief Executive Officer, Co-Founder, Executive Director -
Dr. Denise Scots-Knight Ph.D.,
Co-Founder, CEO & Exec. Director -
Charles Sermon,
Co-Founder, Gen. Counsel & Company Sec. -
Dr. Alastair MacKinnon M.D., MBBS,
Co-Founder and Chief of Portfolio & Pipeline Strategy -
Dr. John P. Richard M.B.A., MBA,
Co-Founder & Chief Bus. Officer -
Dr. John A. Lewicki Ph.D.,
Chief Scientific Officer -
Alexandra Hughes-Wilson,
Chief of Patient Access & Commercial Planning -
Richard Jones,
Chief Financial Officer, Executive Director -
Peter Fellner,
Non-Executive Independent Chairman of the Board -
Anders Ekblom,
Non-Executive Independent Director -
Peter Bains,
Non-Executive Independent Director -
Kunal Kashyap,
Non-Executive Independent Director -
Michael Wyzga,
Non-Executive Independent Director -
Deepa Pakianathan,
Non-Executive Independent Director -
Brian Schwartz,
Director -
Jeremy Bender,
Director -
Wills Hughes-Wilson,
Head of Patient Access, Commercial Planning -
Heidi Petersen,
Senior Vice President, Regulatory Affairs -
Jill Henrich,
U.S. Site Head and Senior Vice President of Regulatory Affairs -
John Richard,
Head of Corporate Development, Co-Founder -
Alastair MacKinnon,
Co-Founder, Chief Medical Officer -
Charles Sermon,
Co-Founder, General Counsel, Company Secretary -
Dr. Arun Mistry,
Therapeutic Area Head of Setrusumab -
Dr. Jackie Parkin,
Therapy Area Head of Respiratory Endocrinology -
Ian Hodgson,
Head of Clinical Operations -
Dr. Fiona Bor,
Head of Intellectual Property -
Dr. John A. Lewicki,
Chief Scientific Officer -
Christine Fox CPA,
Chief Financial Officer -
Jill Henrich,
US Site Head & Sr. VP of Regulatory Affairs -
John Richard,
Co-Founder & Head of Corp. Devel. -
Dr. Alastair MacKinnon,
Co-Founder & Chief Medical Officer -
Dr. Denise Scots-Knight,
Co-Founder, CEO & Exec. Director -
Capital Management Lp Rosen...,
-
Marc J Yoskowitz,
-
Annalisa Jenkins,
-
Daniel Shames,
-
Deepika Pakianathan,
-
Pierre Jacquet,
-
Christine Ann Fox,
Chief Financial Officer -
John A. Lewicki,
Chief Scientific Officer